Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Eastside Medical Center
mi
from
Snellville, GA
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Eastside Medical Center
mi
from
Snellville, GA
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Medical City McKinney - Solis Mammography
mi
from
McKinney, TX
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Medical City McKinney - Solis Mammography
mi
from
McKinney, TX
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Breast Imaging Henry Ford Medical Center Fairlane
mi
from
Dearborn, MI
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Breast Imaging Henry Ford Medical Center Fairlane
mi
from
Dearborn, MI
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Henry Ford Medical Center, New Center One
mi
from
Detroit, MI
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Henry Ford Medical Center, New Center One
mi
from
Detroit, MI
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Henry Ford Medical Center Cottage
mi
from
Grosse Pointe Farms, MI
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Henry Ford Medical Center Cottage
mi
from
Grosse Pointe Farms, MI
Click here to add this to my saved trials
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated:  12/31/1969
Henry Ford Livonia Medical Center
mi
from
Livonia, MI
The STRIVE Study: Breast Cancer Screening Cohort
The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection
Status: Enrolling
Updated: 12/31/1969
Henry Ford Livonia Medical Center
mi
from
Livonia, MI
Click here to add this to my saved trials
Study of Health Effects of Cosmetic Breast Augmentation
Extended Mortality Follow-Up of Women With Augmentation Mammoplasty
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Study of Health Effects of Cosmetic Breast Augmentation
Extended Mortality Follow-Up of Women With Augmentation Mammoplasty
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute , 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
Couple-Focused ACT Intervention for Couples Coping With Cancer: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
Couple-Focused ACT Intervention for Couples Coping With Cancer: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Susceptibility to Breast Cancer
Susceptibility to Breast Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Susceptibility to Breast Cancer
Susceptibility to Breast Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study
Genetic Analysis of Cancer Susceptibility Alleles in the CARE Case-Control Study
Status: Enrolling
Updated:  12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study
Genetic Analysis of Cancer Susceptibility Alleles in the CARE Case-Control Study
Status: Enrolling
Updated: 12/31/1969
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
The Incidence of Breast and Other Cancers Among Female Flight Attendants
The Incidence of Breast and Other Cancers Among Female Flight Attendants
Status: Enrolling
Updated:  12/31/1969
National Institute for Occupational Safety and Health (NIOSH)
mi
from
Cincinnati, OH
The Incidence of Breast and Other Cancers Among Female Flight Attendants
The Incidence of Breast and Other Cancers Among Female Flight Attendants
Status: Enrolling
Updated: 12/31/1969
National Institute for Occupational Safety and Health (NIOSH)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Status: Enrolling
Updated:  12/31/1969
University of Minnesota, School of Public Health Environmental Health Sciences
mi
from
Minneapolis, MN
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
Status: Enrolling
Updated: 12/31/1969
University of Minnesota, School of Public Health Environmental Health Sciences
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors
Reducing Psychological Burdens Among Chinese Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
Herald Cancer Association
mi
from
Los Angeles, CA
Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors
Reducing Psychological Burdens Among Chinese Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
Herald Cancer Association
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors
Reducing Psychological Burdens Among Chinese Breast Cancer Survivors
Status: Enrolling
Updated:  12/31/1969
University of Houston
mi
from
Houston, TX
Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors
Reducing Psychological Burdens Among Chinese Breast Cancer Survivors
Status: Enrolling
Updated: 12/31/1969
University of Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ttuhsc
mi
from
El Paso, TX
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ttuhsc
mi
from
El Paso, TX
Click here to add this to my saved trials
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
A Phase I Trial of Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Recurrent or Refractory Gynecological Cancer Patients
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Toronto,
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Toronto,
Click here to add this to my saved trials
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Santa Monica, CA
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
New York, NY
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
New York, NY
Click here to add this to my saved trials
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Community Hospital Identification of High CV Risk Patients During Cancer Treatment
Community Hospital Identification of High CV Risk Patients During Cancer Treatment (CHI)
Status: Enrolling
Updated:  12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Community Hospital Identification of High CV Risk Patients During Cancer Treatment
Community Hospital Identification of High CV Risk Patients During Cancer Treatment (CHI)
Status: Enrolling
Updated: 12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
El Paso, TX
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated:  12/31/1969
mi
from
Leuven,
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated: 12/31/1969
mi
from
Leuven,
Click here to add this to my saved trials
Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City
Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City
Status: Enrolling
Updated:  12/31/1969
New York University School of Medicine
mi
from
New York, NY
Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City
Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City
Status: Enrolling
Updated: 12/31/1969
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Ironwood Cancer and Research Centers
mi
from
Chandler, AZ
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Ironwood Cancer and Research Centers
mi
from
Chandler, AZ
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Ventura County Hematology and Oncology
mi
from
Oxnard, CA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Ventura County Hematology and Oncology
mi
from
Oxnard, CA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Research Institute Dept of Oncology
mi
from
Davie, FL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Research Institute Dept of Oncology
mi
from
Davie, FL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Watson Clinic Center for Research 1730 Location
mi
from
Lakeland, FL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Watson Clinic Center for Research 1730 Location
mi
from
Lakeland, FL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
John D. Archbold Memorial Hospital John D. Archbold Mem Hosp (4)
mi
from
Thomasville, GA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
John D. Archbold Memorial Hospital John D. Archbold Mem Hosp (4)
mi
from
Thomasville, GA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Joliet Oncology-Hematology Associates Presence Cancer Center
mi
from
Joliet, IL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Joliet Oncology-Hematology Associates Presence Cancer Center
mi
from
Joliet, IL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Englewood Hospital and Medical Center
mi
from
Englewood, NJ
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Englewood Hospital and Medical Center
mi
from
Englewood, NJ
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
PeaceHealth St. Joseph Medical Center
mi
from
Bellingham, WA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
PeaceHealth St. Joseph Medical Center
mi
from
Bellingham, WA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Providence Regional Medical Centre of Everett
mi
from
Everett, WA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Providence Regional Medical Centre of Everett
mi
from
Everett, WA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties Dept.ofNW Med. Specialties
mi
from
Tacoma, WA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties Dept.ofNW Med. Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Cheyenne Regional Medical Center Cheyenne Regional Med Ctr (3)
mi
from
Cheyenne, WY
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Cheyenne Regional Medical Center Cheyenne Regional Med Ctr (3)
mi
from
Cheyenne, WY
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates Arizona Oncology Assoc. (2)
mi
from
Tucson, AZ
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates Arizona Oncology Assoc. (2)
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Shores Medical Group SC
mi
from
Long Beach, CA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Shores Medical Group SC
mi
from
Long Beach, CA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
PCR Oncology
mi
from
Pismo Beach, CA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
PCR Oncology
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Centura Health Research Center Centura Health Research Center
mi
from
Denver, CO
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Centura Health Research Center Centura Health Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Poudre Valley Hospital Poudre Valley Health System
mi
from
Fort Collins, CO
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Poudre Valley Hospital Poudre Valley Health System
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Valley View Hospital Cancer Center
mi
from
Glenwood Springs, CO
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Valley View Hospital Cancer Center
mi
from
Glenwood Springs, CO
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Mid Florida Hematology and Oncology Center
mi
from
Orange City, FL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Mid Florida Hematology and Oncology Center
mi
from
Orange City, FL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Summit Cancer Care Summit Cancer Care (SC)
mi
from
Savannah, GA
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Summit Cancer Care Summit Cancer Care (SC)
mi
from
Savannah, GA
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Mid Illinois Hematology Oncology Mid Illinois Hema/Onc (3)
mi
from
Normal, IL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Mid Illinois Hematology Oncology Mid Illinois Hema/Onc (3)
mi
from
Normal, IL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Alpha Med Physician Group, LLC
mi
from
Tinley Park, IL
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Alpha Med Physician Group, LLC
mi
from
Tinley Park, IL
Click here to add this to my saved trials
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Goshen Center for Cancer SC
mi
from
Goshen, IN
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Goshen Center for Cancer SC
mi
from
Goshen, IN
Click here to add this to my saved trials